TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00185614
Drug: Mycophenolate Mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
Study: NCT03290950
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
Study: NCT00536705
Drug: montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
Study: NCT04250259
Drug: SAMe 400 mg tablet
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
Study: NCT02918630
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
Study: NCT02918630
Drug: E-cigarette
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
Study: NCT03759197
Drug: 188-0551 Spray
Normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Spray containing active drug
Study: NCT03759197
Drug: Vehicle Spray
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Spray containing no active drug
Study: NCT03236805
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
Study: NCT03236805
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
Study: NCT01807741
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Available in 5 and 10 mg.
Study: NCT01283945
Drug: Lucitanib
Normalized name: Lucitanib
DrugBank: Lucitanib (DB11845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)
Study: NCT02062346
Drug: BQ123
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of BQ123 ( selective ETA antagonist )
Study: NCT01575795
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
Study: NCT01575795
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180mg loading dose 180mg loading dose
Study: NCT03048019
Drug: Tirofiban
Normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Tirofiban during the PCI procedure
Study: NCT03048019
Drug: Cangrelor
Normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive Cangrelor during the PCI procedure
Study: NCT00814736
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose on day 14 or day 17
Study: NCT00814736
Drug: sildenafil matching placebo
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose on day 14 or day 17
Study: NCT03397641
Drug: HBI-3000
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule, multi-ion channel blocker
Study: NCT01251211
Drug: botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
Study: NCT01548326
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 40 mg Atorvastatin tablet orally per day for 10 days
Study: NCT04125719
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab infusion
Study: NCT01908699
Drug: Beraprost Sodium 314d Modified Release Tablets
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
Study: NCT02998320
Drug: Genvoya
Normalized name: Genvoya
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral use (one tablet each day); 150/150/200/10 mg; 28 days
Study: NCT02920047
Drug: Fimasartan/Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment B
Study: NCT02920047
Drug: Fimasartan + Amlodipine
Normalized name: fimasartan and amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A
Study: NCT00109668
Drug: beclomethasone dipropionate (QVAR)
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00968045
Drug: Fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
Study: NCT00619242
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets with water by mouth twice a day for two weeks.
Study: NCT03241550
Drug: isavuconazonium sulfate - intravenous
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT03241550
Drug: isavuconazonium sulfate - oral
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT00836901
Drug: amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg-57 mg chewable tablet
Study: NCT02219100
Drug: Home administration of 200 mg mifepristone
Normalized name: mifepristone 200 MG
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home administration of 200 mg mifepristone
Study: NCT04298333
Drug: BP-C1
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days.
Study: NCT01687595
Drug: HerpV and QS-21
DrugBank: QS-21 (DB05400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
Study: NCT02524899
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
Study: NCT00288561
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00706537
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
Study: NCT03422887
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine administration during surgery
Study: NCT03422887
Drug: Flurbiprofen Axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil administration during surgery
Study: NCT01903733
Drug: bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
Study: NCT06499181
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The primary objective is to examine differences in post-operative opioid consumption between the two groups.
Study: NCT06499181
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
Study: NCT06499181
Drug: Epinephrin
Normalized name: Epinephrin
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
Study: NCT02645370
Drug: Danzhen
Normalized name: Danziten
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02645370
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00043784
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02877082
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02877082
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and PO
Study: NCT03480750
Drug: trientine dihydrochloride
Normalized name: trientine dihydrochloride 300 MG Oral Capsule
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
Study: NCT00667979
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
Study: NCT00394225
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00394225
Drug: Helium
Normalized name: Helium
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03480750
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 4 IV D1
Study: NCT04022447
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: retrospective data collection
Study: NCT02617810
Drug: JNJ-42847922
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
Study: NCT02617810
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
Study: NCT01988558
Drug: DL - Lactic Acid
Normalized name: DL-lactic acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
Study: NCT03829683
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/kg/24hours
Study: NCT03829683
Drug: Dextrose 5% in water
Normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mL intravenously every 6 hours
Study: NCT01455844
Drug: CaPre (TM)
Normalized name: Caprelsa
DrugBank: Capreomycin (DB00314)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
Study: NCT01455844
Drug: CaPre (TM)
Normalized name: Caprelsa
DrugBank: Capreomycin (DB00314)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CaPre™ 2.0g daily for 12 weeks
Study: NCT02617810
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
Study: NCT02397473
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT03419624
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg tablet once daily
Study: NCT03419624
Drug: Exenatide 2 mg [Bydureon]
Normalized name: exenatide 2 MG [Bydureon]
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 2 mg injection once weekly
Study: NCT03419624
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily Insulin injections
Study: NCT03419624
Drug: Metformin, if taken before
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
Study: NCT01832194
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT02024971
Drug: Pioglitazone/metformin hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pioglitazone/metformin hydrochloride combination tablets
Study: NCT00019760
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00019760
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01916226
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
Study: NCT01916226
Drug: Cetirizine Placebo
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
Study: NCT00261677
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00723892
Drug: Rebetol (Ribavirin)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
Study: NCT00312091
Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
Study: NCT00312091
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Study: NCT00312091
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Study: NCT00312091
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Study: NCT00020007
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00178828
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
Study: NCT00178828
Drug: bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
Study: NCT03196479
Drug: ketamine and propofol mixture with 1:6 ratio
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
Study: NCT03196479
Drug: ketamine and propofol mixture with 1:4 ratio
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
Study: NCT02420314
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response
Study: NCT02420314
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response
Study: NCT02062684
Drug: Blisibimod
Normalized name: Blisibimod
DrugBank: Blisibimod (DB12330)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02594579
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
Study: NCT02915601
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03019653
Drug: ANX-042
Normalized name: hydroxyzine hydrochloride Oral Tablet [Anx]
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
Study: NCT00135876
Drug: dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04063462
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrotinib, single agent, 400mg p.o once daily until disease progressed
Study: NCT04688294
Drug: Sacubitril-Valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
Study: NCT01848457
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)